San Diego—Obinutuzumab plus bendamustine followed by obinutuzumab maintenance provides an overall survival (OS) advantage over bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma (iNHL), according to updated results from the multinational, Phase III GADOLIN trial.
In this study, presented at the 2016 annual meeting of the American Society of Hematology (abstract 615), 413 patients with rituximab-refractory iNHL were randomly assigned to receive 120
FEBRUARY 9, 2017